Hemispherx Biopharma (HEB) Signs Letter Of Intent With Hollister-Stier Laboratories For The Production Of Ampligen(R)
10/19/2005 5:13:19 PM
PHILADELPHIA--(BUSINESS WIRE)--Oct. 10, 2005--Hemispherx Biopharma, Inc. (AMEX: HEB) has signed a Letter of Intent (LOI) with HollisterStier Laboratories of Spokane, Washington, for the contract manufacturing of Hemispherx's experimental drug, Ampligen(R). The achievement of the initial objectives described in the LOI, in combination with the Polymer production facility under construction in New Brunswick, N.J., will enable Hemispherx to manufacture the Active Pharmaceutical Ingredient (API) for approximately 10,000 doses of Ampligen(R) per week. Based on the LOI, HollisterStier Contract Manufacturing has agreed to fill the Ampligen(R) API from Hemispherx. Production for significantly larger quantities of product are planned thereafter. Hemispherx has already commenced the process of transferring manufacturing technology to HollisterStier.
comments powered by